GETEIN BIOTECH, INC Funds and ETFs Getein Biotech, Inc
Equities
603387
CNE100002RR9
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.04 CNY | +0.44% |
|
+4.75% | -17.82% |
| 2023 | Getein Biotech, Inc Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| 2023 | Getein Biotech, Inc Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
ETFs positioned on Getein Biotech, Inc
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 12 M€ | -16.71% | - | |
| 0.00% | 117 M€ | +1.11% | - |
Getein Biotech Inc is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The Company also provides testing and agency services. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.82% | 633M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- 603387 Stock
- Funds and ETFs Getein Biotech, Inc
